IPO Update: Avedro Files Proposed Terms For IPO

Summary

  • Avedro aims to raise $75 million from the sale of its common stock in an IPO.
  • The firm is commercializing corneal shaping and repair technologies in the U.S.
  • Given strong demographic growth, the trend toward less-invasive treatments, existing CE mark approval in Europe and reasonable valuation assumptions, the IPO looks enticing.
  • This idea was discussed in more depth with members of my private investing community, IPO Edge. Start your free trial today ยป

Quick Take

Avedro (AVDR) intends to raise $75 million from the sale of its common stock in an IPO, per an amended regulatory filing.

The company sells corneal repair medical instruments to eye doctors and is seeking FDA approval for its European-approved system for correcting near-sightedness (presbyopia).

Given the approved status of the much larger market opportunity Mosaic system in Europe, the growth opportunity from its commercialization and approval processes in the U.S., and the reasonable valuation assumptions, the IPO is one to watch closely.

READ FULL ARTICLE HERE